WO2004112757A1 - Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug - Google Patents
Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug Download PDFInfo
- Publication number
- WO2004112757A1 WO2004112757A1 PCT/CA2004/000561 CA2004000561W WO2004112757A1 WO 2004112757 A1 WO2004112757 A1 WO 2004112757A1 CA 2004000561 W CA2004000561 W CA 2004000561W WO 2004112757 A1 WO2004112757 A1 WO 2004112757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- alkyl
- poly
- butyl
- supramolecular assemblies
- Prior art date
Links
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 54
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 229940079593 drug Drugs 0.000 title claims abstract description 19
- 229920001400 block copolymer Polymers 0.000 title abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 60
- 238000000429 assembly Methods 0.000 claims abstract description 51
- 230000000712 assembly Effects 0.000 claims abstract description 51
- -1 poly(ethylene oxide) Polymers 0.000 claims abstract description 50
- 239000000693 micelle Substances 0.000 claims abstract description 38
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 29
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 21
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 15
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000013543 active substance Substances 0.000 claims abstract description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 10
- 230000007613 environmental effect Effects 0.000 claims abstract description 8
- 150000001768 cations Chemical class 0.000 claims abstract description 5
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 24
- 229960002297 fenofibrate Drugs 0.000 claims description 23
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 125000002091 cationic group Chemical group 0.000 claims description 10
- 238000010348 incorporation Methods 0.000 claims description 6
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 5
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 claims description 5
- 229960000881 verapamil hydrochloride Drugs 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical group 0.000 claims description 2
- 229920000359 diblock copolymer Polymers 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000002349 favourable effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 22
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000000186 progesterone Substances 0.000 description 11
- 229960003387 progesterone Drugs 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 5
- 229920000831 ionic polymer Polymers 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012867 bioactive agent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005266 casting Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011258 core-shell material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to stimuli responsive amphiphilic polymers forming supramolecular assemblies or micelles in the nanometric size range under favourable conditions. These supramolecular assemblies or micelles can be useful for the oral or parenteral delivery of hydrophobic or cationic pharmaceutical agents.
- Amphiphilic block copolymers having optimal hydrophilic and hydrophobic segments self-assemble spontaneously in aqueous environment forming micelles or supramolecular assemblies. These supramolecular assemblies exhibit core-shell architecture wherein the hydrophobic part forms the core and the hydrophilic part forms the corona.
- polymeric micelles have been widely used as drug delivery carriers for parenteral administration. Micellar dmg delivery carriers have several advantages including biocompatibility, solubilization of hydrophobic drugs in the core, nanometric size ranges which facilitate extravasation of the dmg carrier at the site of inflammation, site-specific delivery etc.
- block copolymers for parenteral delivery examples include poly(ethylene oxide)-b-poly(D,L-lactide), poly(ethylene oxide)-b-poly( ⁇ -caprolactone), poly(ethylene oxide)-b-poly(aspartic acid), poly(N-vinyl pyrrolidone)-b-poly(D,L-lactide) etc.
- US Patent 6,322,805 describes polymeric dmg carrier micelles prepared from amphiphilic block copolymer having a hydrophilic poly(alkylene oxide) component and a biodegradable hydrophobic component selected from a group consisting of poly(lactic acid), poly(lactic-co-glycolic acid), poly( ⁇ -caprolactone) and a derivative thereof. These micelles are capable of solubilizing hydrophobic dmg in a hydrophilic environment.
- US Patent 6,338,859 describes polymeric micelle compositions where the hydrophilic component includes poly(N-vinyl-2-pyrrolidone) and the hydrophobic component is selected from a group consisting of polyesters, polyorthoesters, polyanhydride and derivatives thereof.
- the polyester group can be selected from poly(D,L- lactic acid), poly(glycolic acid), lactide/glycolide copolymers, poly( ⁇ -caprolactone) and derivatives thereof.
- the micelle composition contains a therapeutic agent which can be an antitumor compound, hydrophobic antibiotic, hydrophobic antifungal agent, an immunomodulator, an antiviral dmg , or the like.
- US Patent 6,383,811 describes formation of complexes of polyions such as DNA with polyampholytes i.e. polymers possessing both cationic and anionic moieties, and delivery of the complex into the cell.
- US Patent 6,210,717 describes a composition composed of mixed polymeric micelles made of amphiphilic polyester-polycation copoly er and an amphiphilic polyester-sugar copolymer for delivery of nucleic acids into targeted host cells.
- the polyester-polycation forms an electrostatic interaction with polyanionic nucleic acids, and the polyester-sugar copolymer directs the micelle-nucleic acid complex to cells in vivo.
- US Patent 6,429,200 describes delivery of polynucleotides to cells using cleavable reverse micelles. Other molecules such as polymers, and surfactants containing disulphide linkages can be included into the complex micelles to enhance the delivery.
- US Patent 5,510,103 describes block copolymers having the hydrophilic and hydrophobic segments forming micelles and entrapping the hydrophobic drugs by physical methods.
- the hydrophilic segment is preferably poly(ethylene oxide) and hydrophobic segment is preferably poly( ⁇ -benzyl -L-aspartate) while the preferred dmg is adriamycin.
- US Patent 5,955,509 describes use of poly(vinyl-N-heterocycle)-b-poly(alkylene oxide) copolymers in micelle containing pharmaceutical formulations. These copolymers respond to pH changes in the environment and can be used to deliver therapeutic compounds at lower pH values. The micelles of these polymers remain intact at neutral pH, e.g.
- US Patent 6,497,895 describes hyperbranched micelles containing a core of mucic acid esters for the encapsulation of hydrophobic molecules. These polymers are useful for the transdermal delivery of the entrapped agent in a controlled manner.
- US Patent 6,387,406 describes compositions of the poly(oxyethylene)- poly(oxypropylene) block copolymers for oral delivery of biological agents.
- Nishiyama et al (Phar Res 2001, 18, 1035-1041 ; J Controlled Release 2001, 74, 83-94) have described the use of poly(ethylene oxide)-b-poly( ⁇ , ⁇ -aspartic acid) block copolymers forming micelles by interaction with an antitumor dmg, specifically cisplatin. Though the majority of these polymers can be used for oral delivery of bioactive agents, what is presently lacking are amphiphilic polymers capable of forming supramolecular assemblies that respond to an environmental stimuli such as pH change, thereby entrapping the contents in the micelle core at a low pH, such as that prevailing in the stomach, and rapidly releasing the contents at a higher pH, such as that prevailing in the intestine.
- an environmental stimuli such as pH change
- the present invention relates to polymers useful in combination with pharmaceutical compositions containing at least one biologically active agent. More particularly, the invention relates to block copolymers having hydrophilic and hydrophobic segments suitable for, but not limited to, oral drag delivery. More particularly, the hydrophilic segment of the polymers is nonionic and the hydrophobic segment contains at least one reversibly ionizable pendant carboxyl group conferring pH-sensitivity to the polymers. Accordingly, it is a primary objective of the instant invention to provide a copolymerf which is composed of a hydrophilic segment made of poly(ethylene oxide) and a hydrophobic segment composed of vinyl monomers containing at least one pendant carboxyl group.
- the vinyl monomers included in the polymer are acrylic acid or methacrylic acid having pendant carboxyl groups and butyl (alkyl)acrylate where the butyl segment can be a linear or branched chain.
- the hydrophobic segment is a mixture of non-ionizable butyl (alkyl)acrylate and ionizable (alkyl)acrylic acid which controls the hydrophobicity of the polymer.
- Another objective of the instant invention is to prepare pharmaceutical compositions from the instantly disclosed polymers by entrapping at least one substance, preferably a biologically active agent, which is illustrated by, albeit not limited to a hydrophobic molecule, a cationic compound or macromolecule such as peptides and proteins bearing cationic residues.
- the entrapment can be physical (e.g. hydrophobic interaction, electrostatic interaction), or chemical (e.g. covalent linkage) in nature.
- a further objective of the present invention is to prepare supramolecular assemblies having core-shell structure wherein th ⁇ icore is formed by the hydrophobic segment, which can reversibly dissociate and associate in response to a change in environmental pH because of the pendant carboxyl group.
- the size of these supramolecular assemblies can be between 5 to 1000 nanometers thereby forming a solution or colloidal dispersion in water. It is to be noted that in the further text terms "micelles” and “supramolecular assemblies” are used interchangeably and essentially mean structures having a size range of between about 5 to 1000 nanometers.
- Yet another objective of the instant invention is to describe methods of entrapping the hydrophobic agents and cationic molecules in the supramolecular assemblies giving high incorporation efficiencies.
- a still further objective of the present invention is to use these supramolecular assemblies for delivery of a bioactive agent into the body by, but not limited to, the oral route.
- the hydrophobic molecule trapped in the core of the supramolecular assembly will be protected from the harsh acidic conditions of the stomach and released in the intestine due to dissociation of micelle at high pH.
- Figure 1 demonstrates in vitro release of progesterone from PEO-b-poly(nBAso-co- MAA 50 ) supramolecular assemblies as a function of pH;
- Figure 2 demonstrates the effect of pH on intensity of light scattered by solution of PEO- b-poly(nBA5o-co-MAA 5 o);
- Figure 3. is a plot of plasma concentration versus time of fenofibrate upon oral administration of different formulations to Sprague-Dawley rats.
- nBA - n-butyl acrylate MAA - methacrylic acid
- EA - ethyl acrylate PEO - poly(ethylene oxide).
- the present invention describes pharmaceutical compositions composed of block polymers composed of a poly(ethylene oxide) forming the hydrophilic segment and a poly(butyl (alkyl)acrylate-co-(alkyI)acrylic acid) forming the hydrophobic segment; and at least one biologically active agent.
- the molecular weight of the hydrophilic segment can be in the range of 200 to 80,000 Da, more preferably in the range of 500 to 10,000 Da, still more preferably in the range of 2,000 to 5,000 Da.
- the hydrophobic segments of the polymers in the present invention are composed of butyl (alkyl)acrylate and (alkyl)acrylic acid, where the alkyl chain is composed of from 0 to about 10 carbon atoms, inclusively, more preferably with 0 or 1 carbon atom.
- the butyl segment of the butyl (alkyl)acrylate can be a linear or branched chain including without limitation n-butyl and tert-butyl groups.
- the mole ratio of the butyl (alkyl)acrylate : (alkyl)acrylic acid in the hydrophobic segment is in the range of about 5:95 to 95:5, more preferably in the range of about 30:70 to 70:30.
- the length of the hydrophobic segment can be in the range of about 200 to 50,000, more preferably in the range of about 500 to 80,000 Da.
- Amphiphilic block copolymers have a tendency to self-assemble in water forming micelles. Upon micellization, the hydrophobic segment forms a core and the hydrophilic segment forms the corona of the micelles. The core of these micelles can be used as a reservoir of hydrophobic compounds protecting them form the external environment. If the hydrophobic segment of the polymer contains reversibly ionizable moieties, then the hydrophobicity of the segment could be manipulated by controlling the ionization of the moiety. Polymers of the present invention differ from other block copolymers in this aspect.
- the hydrophobic segment is composed of the mixture of two monomers, one of them is butyl (alkyl) acrylate, which confers hydrophobicity to the segment.
- Butyl (alkyl)acrylate monomer is more preferably butyl acrylate or butyl methacrylate.
- the other monomer, (alkyl)acrylic acid has a pendant carboxyl group that can be reversibly ionized by changing the environmental pH.
- the environmental pH is below the pKa of the carboxyl group, it will remain mostly in the unionized form and will confer hydrophobicity to the segment. This results in spontaneous aggregation of polymeric chains forming stable supramolecular assemblies or micelles in aqueous environment.
- (Alkyl)acrylic acid monomer is more preferably acrylic acid or methacrylic acid.
- These supramolecular assemblies are in the size range of from about 5 to 1000 nanometers. Hydrophobic drags are incorporated in the core of such supramolecular assemblies by methods that are known to one of ordinary skill in the art (see for example Lavasanifar et al J Controlled Release 2001, 77,155-60; Kohori et J Controlled Release 2002,78,155-63).
- Manipulation of the composition of the hydrophobic segment results in variation in the hydrophobicity of the polymer allowing control of the incorporation efficiencies of the hydrophobic drugs.
- Loadings in the range of 0.1 to 50% w/w more preferably in the range of 1 to 20% w/w of hydrophobic drugs are obtained using different drug loading procedures.
- Block copolymers of the present invention are used to prepare pharmaceutical compositions containing hydrophobic molecules.
- Non-limiting examples of the hydrophobic molecules includes hypolipidemic agents such as fenofibrate, anticancer agents such as doxorubicin, paclitaxel, docetaxel, camptothecin, megestrol acetate, teniposide, etoposide, antihypertensive agents such as candesartan cilexetil, non-steroidal, anti-inflammatory agents such as indomethacin, celecoxib, antiviral agents such as retinovir, amprenavir, indinavir, efavirenz, immunosuppressive agents such as cyclosporin A, sirolimus, tacrolimus, and similar agents belonging to other therapeutic classes.
- hypolipidemic agents such as fenofibrate
- anticancer agents such as doxorubicin, paclitaxel, docetaxel, camptothecin, megestrol acetate, teniposide, etoposide, antihypertensive
- the poly(butyl (alkyl)acrylate-co-(alkyl)acrylic acid) segment of the polymer will bear a negative charge at a pH above the pKa of carboxyl groups and form complexes with cationic molecules including without limitation polycations, peptides and proteins bearing cationic residues by electrostatic interactions. This will result in the partial or complete charge neutralization of polymer and/or cationic molecule thereby forming supramolecular assemblies or micelles. The cation or polycationic molecule will be entrapped in the core of such supramolecular assemblies.
- cationic residues refers to the functional groups imparting positive charge to the molecule such as cationic amino acids e.g.
- lysine arginine, histidine or other functional groups such as primary, secondary, tertiary or quaternary amine groups present in the molecule.
- the complexes of poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with poly-1-lysine are prepared in a buffer solution at pH 7.4.
- Supramolecular assemblies having unimodal size distribution within the size range of about 20 to 50 nm are obtained depending upon the molecular weight of the poly-1-lysine and composition of the polymer.
- complexes of poly(ethylene oxide)-block-poIy(ethyl acrylate-co-methacrylic acid) with poly-1-lysine in pH 7.4 buffer results in formation of aggregates having multimodal size distribution with sizes above about 200 nm.
- block copolymers are used to form stable coordination complexes with biologically active agents illustrated as metallic compounds such as cisplatin, carboplatin above the pKa of the carboxyl groups.
- biologically active agents illustrated as metallic compounds such as cisplatin, carboplatin above the pKa of the carboxyl groups.
- the presence of butyl (alkyl)acrylate in the hydrophobic segment plays several crucial roles in forming stable supramolecular assemblies.
- polymers with improved characteristics could be obtained by incorporating butyl (alkyl)acrylate in the hydrophobic segment.
- One of the major advantages of polymers in accordance with the present invention is the presence of the butyl chain of the butyl (alkyl)acrylate that largely minimizes formation of such hydrogen bonding complexes and can prevent formation of aggregates. This aids in the formation of stable supramolecular assemblies having uniform size range.
- poly(ethylene oxide)-block-poly(n-butyl acrylate-co-methacrylic acid) with 50:50 mole ratio of n-butyl acrylate:methacrylic acid having molecular weight of about 5300 Da forms micelles of 30 nm at pH 5.0
- poly(ethylene oxide)-block- poly(ethyl acrylate-co-methacrylic acid) with 50:50 mole ratio of ethyl acrylate: methacrylic acid having molecular weight of about 5100 Da forms micelles of 120 nm at pH 5.0, which are possibly aggregates of several micelles.
- An oral route is the most preferred route of administration for a pharmaceutically active agent.
- compositions can be used in the form of tablets, capsules, powders, lozenges, solutions, suspensions, syrups, elixirs, and the like.
- the pharmaceutical compositions of the present invention are administered orally.
- the pharmaceutical compositions of the present invention can also be administered by a number of other routes, including without limitation, rectally, vaginally, topically, by pulmonary route, parenterally, including but not limited to intravenous, intra-arterial, intramuscular, intraperitoneal or subcutaneous route.
- the polymers in the present invention can be modified to attach targeting ligands such as lectin, antibodies or fragments of antibodies, peptides, vitamins or sugar molecules.
- figures appearing as subscript in the polymer composition indicate the mole ratio of that monomer present in the hydrophobic segment of the polymer.
- Progesterone was used as a model hydrophobic drug to evaluate the effect of pH on drug release from supramolecular assemblies.
- 3 H-progesterone was loaded in the supramolecular assemblies of PEO-b-poly(nBA 5 o-co-MAA 5 o) of molecular weight 5300 Da by film casting method. Briefly, 10 mg polymer, 1 mg progesterone and 1 ⁇ Ci 3 H- progesterone were dissolved in a mixture of dichloromethane, ethanol and water in a scintillation vial. The solvents were evaporated under reduced pressure to cast a film of polymer and drug on the glass surface.
- the film was hydrated with water to obtain the supramolecular assemblies, this solution was filtered through 2 ⁇ m filter to remove precipitated drag.
- the solution of progesterone loaded supramolecular assemblies was filled in a dialysis bag (6000-8000 Da molecular weight cut off) and the bag was put in a beaker containing 200 mL of simulated gastric fluid, pH 1.2 maintained at 37°C.
- the release medium was magnetically stirred. After 2 hours, the pH of medium was adjusted to 7.2 by addition of sodium hydroxide and potassium dihydrogen phosphate. During the entire release experiment, 1 mL samples of release medium were withdrawn periodically to measure the radioactivity of 3 H-progesterone.
- Fenofibrate was used as a model poorly water-soluble hydrophobic drug to evaluate the effect of drug incorporation in supramolecular assemblies on the bioavailability upon oral administration to rats.
- FNB incorporation was studied in different PEO-b-poly(EA-co-MAA) and PEO-b-poly(nBA5 ⁇ r CO-MAA 50 ) polymers by emulsion and film casting methods. The FNB loading was higher in PEO-b-poly(nBA5o-co-MAA5o) polymers.
- FNB loaded supramolecular assemblies were prepared from PEO-b-poIy(nBAso-co-MAA 5 o) of about molecular weight 5300 Da by film casting method. Size of the supramolecular assemblies was in the range of about 100-300 nm.
- FNB standard formulation was prepared by suspending the powder from Lipidil Macro® (Foumier) capsule in 0.5% w/v , carboxymethyl cellulose sodium (CMC Na) solution to obtain uniform suspension.
- FNB powder (Sigma) was also suspended in 0.5% w/v CMC Na solution to prepare resuspended FNB formulation which acts as a negative control. Rats were divided into 3 groups of 6 animals each. The rats were fasted overnight and fed with standard diet throughout the study. Each formulation was administered orally at a dose of 7.5 g/kg to 6 rats from a group. Blood was removed periodically from each rat, plasma was separated and stored at -80°C till further use. FNB content from the plasma was determined and plotted against time, the results of which are shown in Figure 3.
- Example 3 Formation of polyion complex micelles of PEO-ft-P(nBAso-co-MAAso) with poly-l- lysine
- Poly-1-lysine (PLL) of molecular weight 16,100 was used as a model cationic compound for formation of polyion micelles with PEO-b-P(EA 50 -co-MAA5o) and PEO-b-P(nBA5o-co- MAA 50 ) copolymers with molecular weights of 5100 and 5700 Da, respectively.
- Polymer: PLL (-/+) charge ratios (mole: mole) of 1 : 1 and 2: 1 were used for complex formation.
- Example 4 Complexation of PEO-b-P(nBA so -co-MAA S o) with verapamil hydrochloride
- Verapamil hydrochloride was used as a model cationic drug. Solutions of PEO-b-P(nBA 50 - co-MAA 50 ) and verapamil hydrochloride in universal buffer were mixed to obtain final polymer concentration of 0.5 mg/mL and verapamil hydrochloride concentration of 0.8 mg/mL. The solution pH was adjusted to 6.1 and size was measured using DLS. Polyion complex micelles of 38 ⁇ 10.3 nm were obtained. All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0411872-3A BRPI0411872A (en) | 2003-06-25 | 2004-04-14 | pharmaceutical composition |
PL04727195T PL1638539T3 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
DK04727195T DK1638539T3 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising pH-sensitive block copolymers and a hydrophobic drug |
AU2004248863A AU2004248863B2 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising pH-sensitive block copolymers and a hydrophobic drug |
JP2006515571A JP4619357B2 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical composition comprising a pH sensitive block copolymer and a hydrophobic drug |
SI200431088T SI1638539T1 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
EP04727195A EP1638539B1 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
DE602004018772T DE602004018772D1 (en) | 2003-06-25 | 2004-04-14 | PHARMACEUTICAL COMPOSITIONS - CONTAINING PH SENSITIVE BLOCK COPOLYMERS AND A HYDROPHOBIC ACTIVE SUBSTANCE |
MXPA05014017A MXPA05014017A (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug. |
CA2530736A CA2530736C (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/607,446 | 2003-06-25 | ||
US10/607,446 US7094810B2 (en) | 2001-06-08 | 2003-06-25 | pH-sensitive block copolymers for pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004112757A1 true WO2004112757A1 (en) | 2004-12-29 |
Family
ID=33540273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/000561 WO2004112757A1 (en) | 2003-06-25 | 2004-04-14 | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
Country Status (16)
Country | Link |
---|---|
US (1) | US7094810B2 (en) |
EP (1) | EP1638539B1 (en) |
JP (1) | JP4619357B2 (en) |
AT (1) | ATE418970T1 (en) |
AU (1) | AU2004248863B2 (en) |
BR (1) | BRPI0411872A (en) |
CA (1) | CA2530736C (en) |
CY (1) | CY1110264T1 (en) |
DE (1) | DE602004018772D1 (en) |
DK (1) | DK1638539T3 (en) |
ES (1) | ES2323701T3 (en) |
MX (1) | MXPA05014017A (en) |
PL (1) | PL1638539T3 (en) |
PT (1) | PT1638539E (en) |
SI (1) | SI1638539T1 (en) |
WO (1) | WO2004112757A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005079856A1 (en) * | 2004-02-23 | 2005-09-01 | The University Of British Columbia | Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules |
WO2008035229A2 (en) * | 2006-09-22 | 2008-03-27 | Labopharm, Inc. | Compositions and methods for ph targeted drug delivery |
WO2009050555A2 (en) * | 2007-10-19 | 2009-04-23 | Coatex S.A.S. | Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
EP2305275A1 (en) * | 2008-06-24 | 2011-04-06 | NanoCarrier Co., Ltd. | Liquid composition comprising cisplatin-coordinating compound |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003523544A (en) * | 2000-02-17 | 2003-08-05 | レックスマーク・インターナショナル・インコーポレーテツド | Composition containing fine particles for supporting biologically active substance thereon or having the same supported thereon and method for preparing these |
US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
US20060198891A1 (en) | 2004-11-29 | 2006-09-07 | Francois Ravenelle | Solid formulations of liquid biologically active agents |
US20090074872A1 (en) * | 2006-06-26 | 2009-03-19 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
RU2009102262A (en) * | 2006-06-26 | 2010-08-10 | Мьючуал Фармасьютикал Компани, Инк. (Us) | COMPOSITIONS OF ACTIVE AGENT, WAYS OF THEIR OBTAINING AND WAYS OF APPLICATION |
JP5340956B2 (en) * | 2006-12-20 | 2013-11-13 | アーケマ・インコーポレイテッド | Encapsulation and / or binding of polymers |
WO2008128292A1 (en) * | 2007-04-20 | 2008-10-30 | University Of South Australia | Nanoparticle-coated capsule formulation for dermal drug delivery |
JP2010539245A (en) * | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | Drug carrier |
TWI388591B (en) * | 2008-03-28 | 2013-03-11 | Ind Tech Res Inst | Thermosensitive material |
US8778400B2 (en) * | 2008-04-21 | 2014-07-15 | University Of South Australia | Nanoparticle-stabilized capsule formulation for treatment of inflammation |
AU2009246321A1 (en) * | 2008-05-13 | 2009-11-19 | Phaserx, Inc. | Polymeric carrier |
CN102066444A (en) | 2008-05-13 | 2011-05-18 | 华盛顿大学 | Micellic assemblies |
WO2009140427A2 (en) | 2008-05-13 | 2009-11-19 | University Of Washington | Diblock copolymers and polynucleotide complexes thereof for delivery into cells |
WO2009140423A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Targeted polymer bioconjugates |
WO2009140432A2 (en) * | 2008-05-13 | 2009-11-19 | University Of Washington | Micelles for intracellular delivery of therapeutic agents |
CA2724004C (en) * | 2008-05-16 | 2016-08-23 | The University Of Sydney | Administrable compositions comprising particulate material dispersed throughout a liquid carrier |
CA2635187A1 (en) | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
CA2734917A1 (en) | 2008-08-22 | 2010-02-25 | University Of Washington | Heterogeneous polymeric micelles for intracellular delivery |
CA2742955A1 (en) | 2008-11-06 | 2010-05-14 | University Of Washington | Bispecific intracellular delivery vehicles |
KR20110095292A (en) | 2008-11-06 | 2011-08-24 | 유니버시티 오브 워싱톤 | Multiblock copolymers |
JP2012511053A (en) | 2008-12-08 | 2012-05-17 | ユニヴァーシティ オブ ワシントン | Omega functionalized polymers, junction functionalized block copolymers, and radical chain extension polymerization |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
TWI374903B (en) * | 2008-12-31 | 2012-10-21 | Ind Tech Res Inst | Biodegradable copolymer hydrogel materials |
WO2011062965A2 (en) | 2009-11-18 | 2011-05-26 | University Of Washington Through Its Center For Commercialization | Targeting monomers and polymers having targeting blocks |
CA2919828C (en) | 2013-07-30 | 2022-07-19 | Phaserx, Inc. | Block copolymers and their conjugates or complexes with oligonucleotides |
CA2974503A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
JP2019513151A (en) | 2016-03-08 | 2019-05-23 | ロス ガトス ファーマスーティカルズ, インク.Los Gatos Pharmaceuticals, Inc. | Camptothecin derivatives and uses thereof |
WO2017156191A1 (en) | 2016-03-08 | 2017-09-14 | Los Gatos Pharmaceuticals, Inc. | Composite nanoparticles and uses thereof |
CN106432647B (en) * | 2016-09-26 | 2018-10-30 | 华南理工大学 | PH response block polymers and its mixed micelle based on tertiary amino and application |
WO2018126084A1 (en) | 2016-12-30 | 2018-07-05 | Phaserx, Inc. | Branched peg molecules and related compositions and methods |
WO2019032975A1 (en) * | 2017-08-10 | 2019-02-14 | Mec Device Pharma International Llc | Abuse-resistant drug formulations |
CN114377144A (en) * | 2022-01-28 | 2022-04-22 | 南通大学 | PH/active oxygen dual-responsive supramolecular polypeptide prodrug nanoparticle |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955509A (en) * | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
WO2001087227A2 (en) * | 2000-05-17 | 2001-11-22 | Labopharm, Inc. | Drug containing polymeric micelles |
US6491903B1 (en) * | 1996-06-27 | 2002-12-10 | Washington University | Particles comprising amphiphilic copolymers |
WO2004035013A2 (en) * | 2002-10-21 | 2004-04-29 | L'oreal | Process for dissolving lipophilic compounds, and cosmetic composition |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1411843A (en) * | 1973-02-28 | 1975-10-29 | Univ Strathclyde | Method of modifying the properties of a polymer |
JPS5767860A (en) * | 1980-10-15 | 1982-04-24 | Fuji Photo Film Co Ltd | Material for multilayer analysis |
JP2517760B2 (en) | 1989-05-11 | 1996-07-24 | 新技術事業団 | Water-soluble polymerized pharmaceutical preparation |
KR940003548U (en) | 1992-08-14 | 1994-02-21 | 김형술 | Laundry dryer |
US5840319A (en) | 1992-10-08 | 1998-11-24 | Alakhov; Valery Yu | Biological agent compositions |
EP0639592A1 (en) * | 1993-08-18 | 1995-02-22 | Nippon Shokubai Co., Ltd. | Water-soluble graft polymers and production process thereof |
US5786387A (en) | 1994-03-23 | 1998-07-28 | Meiji Seika Kabushiki Kaisha | Lipid double-chain derivative containing polyoxyethylene |
US5620850A (en) | 1994-09-26 | 1997-04-15 | President And Fellows Of Harvard College | Molecular recognition at surfaces derivatized with self-assembled monolayers |
US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
US6221959B1 (en) | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US5656611A (en) | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
WO1996021036A2 (en) | 1994-12-30 | 1996-07-11 | Chiron Viagene, Inc. | Nucleic acid condensing agents with reduced immunogenicity |
US5492996A (en) * | 1995-02-21 | 1996-02-20 | The United States Of America As Represented By The Secretary Of The Air Force | Alcohol soluble benzazole polymers |
CN1085987C (en) | 1995-04-19 | 2002-06-05 | 片冈一则 | Heterotelechelic block copolymers and process for producing same |
US5908777A (en) | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
NZ313769A (en) | 1995-08-10 | 2000-02-28 | Kazunori Kataoka | block polymer having a functional group presented on each end |
US5770627A (en) | 1995-08-16 | 1998-06-23 | University Of Washington | Hydrophobically-modified bioadhesive polyelectrolytes and methods relating thereto |
US5702717A (en) | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
DE69707853T2 (en) | 1996-03-15 | 2002-06-27 | President And Fellows Of Harvard College, Cambridge | METHOD FOR SHAPING OBJECTS AND MICROSTRUCTURING SURFACES BY MOLDING WITH CAPILLARY EFFECT |
GB9623051D0 (en) | 1996-11-06 | 1997-01-08 | Schacht Etienne H | Delivery of DNA to target cells in biological systems |
AU733692B2 (en) | 1997-02-28 | 2001-05-24 | Regents Of The University Of California, The | Inhibition of cell-cell binding by lipid assemblies |
EP0963758A3 (en) | 1998-05-07 | 2000-03-22 | Universiteit Gent | Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells |
US5939453A (en) | 1998-06-04 | 1999-08-17 | Advanced Polymer Systems, Inc. | PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers |
CN1313873A (en) | 1998-07-13 | 2001-09-19 | 表达遗传学公司 | Polyester analogus of poly-L-Lysine as a soluble, biodegradable gene delivery carrier |
DE19919785A1 (en) | 1999-04-30 | 2000-12-07 | Wella Ag | Hair treatment agent with polymers of unsaturated saccharides, unsaturated saccharic acids or their derivatives |
DE10008895A1 (en) | 2000-02-25 | 2001-08-30 | Beiersdorf Ag | Stabilization of active substances that are sensitive to oxidation and / or UV |
US6939564B2 (en) * | 2001-06-08 | 2005-09-06 | Labopharm, Inc. | Water-soluble stabilized self-assembled polyelectrolytes |
US6780428B2 (en) | 2001-06-08 | 2004-08-24 | Labopharm, Inc. | Unimolecular polymeric micelles with an ionizable inner core |
GB0131112D0 (en) * | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
-
2003
- 2003-06-25 US US10/607,446 patent/US7094810B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 WO PCT/CA2004/000561 patent/WO2004112757A1/en active Application Filing
- 2004-04-14 CA CA2530736A patent/CA2530736C/en not_active Expired - Lifetime
- 2004-04-14 AU AU2004248863A patent/AU2004248863B2/en not_active Ceased
- 2004-04-14 ES ES04727195T patent/ES2323701T3/en not_active Expired - Lifetime
- 2004-04-14 MX MXPA05014017A patent/MXPA05014017A/en active IP Right Grant
- 2004-04-14 DK DK04727195T patent/DK1638539T3/en active
- 2004-04-14 JP JP2006515571A patent/JP4619357B2/en not_active Expired - Lifetime
- 2004-04-14 SI SI200431088T patent/SI1638539T1/en unknown
- 2004-04-14 PT PT04727195T patent/PT1638539E/en unknown
- 2004-04-14 EP EP04727195A patent/EP1638539B1/en not_active Expired - Lifetime
- 2004-04-14 AT AT04727195T patent/ATE418970T1/en active
- 2004-04-14 PL PL04727195T patent/PL1638539T3/en unknown
- 2004-04-14 DE DE602004018772T patent/DE602004018772D1/en not_active Expired - Lifetime
- 2004-04-14 BR BRPI0411872-3A patent/BRPI0411872A/en not_active IP Right Cessation
-
2009
- 2009-03-31 CY CY20091100371T patent/CY1110264T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955509A (en) * | 1996-05-01 | 1999-09-21 | Board Of Regents, The University Of Texas System | pH dependent polymer micelles |
US6491903B1 (en) * | 1996-06-27 | 2002-12-10 | Washington University | Particles comprising amphiphilic copolymers |
WO2001087227A2 (en) * | 2000-05-17 | 2001-11-22 | Labopharm, Inc. | Drug containing polymeric micelles |
WO2004035013A2 (en) * | 2002-10-21 | 2004-04-29 | L'oreal | Process for dissolving lipophilic compounds, and cosmetic composition |
Non-Patent Citations (1)
Title |
---|
FREIJ-LARSSON C ET AL: "Polyurethane surfaces modified by amphiphilic polymers: effects on protein adsorption", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 3, February 2000 (2000-02-01), pages 307 - 315, XP004243982, ISSN: 0142-9612 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005079856A1 (en) * | 2004-02-23 | 2005-09-01 | The University Of British Columbia | Drug delivery compositions comprising hydrophobic polymers and amphipathic molecules |
WO2008035229A2 (en) * | 2006-09-22 | 2008-03-27 | Labopharm, Inc. | Compositions and methods for ph targeted drug delivery |
WO2008035229A3 (en) * | 2006-09-22 | 2009-08-13 | Labopharm Inc | Compositions and methods for ph targeted drug delivery |
JP2010504318A (en) * | 2006-09-22 | 2010-02-12 | ラボファーム インコーポレイテッド | Compositions and methods for pH targeted drug delivery |
WO2009050555A2 (en) * | 2007-10-19 | 2009-04-23 | Coatex S.A.S. | Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
FR2922452A1 (en) * | 2007-10-19 | 2009-04-24 | Coatex S A S Soc Par Actions S | FORMULATIONS OF ORGANOPLATINIC COMPOUNDS IN THE PRESENCE OF ASSOCIATIVE POLYMERS, PRODUCTS OBTAINED AND USES THEREOF |
WO2009050555A3 (en) * | 2007-10-19 | 2009-06-04 | Coatex Sas | Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
EP2305275A1 (en) * | 2008-06-24 | 2011-04-06 | NanoCarrier Co., Ltd. | Liquid composition comprising cisplatin-coordinating compound |
EP2305275A4 (en) * | 2008-06-24 | 2012-07-18 | Nanocarrier Co Ltd | Liquid composition comprising cisplatin-coordinating compound |
US8895076B2 (en) | 2008-06-24 | 2014-11-25 | Nanocarrier Co., Ltd. | Liquid composition of cisplatin coordination compound |
Also Published As
Publication number | Publication date |
---|---|
EP1638539A1 (en) | 2006-03-29 |
MXPA05014017A (en) | 2007-01-31 |
CY1110264T1 (en) | 2015-01-14 |
DE602004018772D1 (en) | 2009-02-12 |
CA2530736A1 (en) | 2004-12-29 |
ATE418970T1 (en) | 2009-01-15 |
SI1638539T1 (en) | 2009-10-31 |
AU2004248863B2 (en) | 2009-03-12 |
JP2007505029A (en) | 2007-03-08 |
DK1638539T3 (en) | 2009-05-04 |
US7094810B2 (en) | 2006-08-22 |
BRPI0411872A (en) | 2006-08-08 |
US20040072784A1 (en) | 2004-04-15 |
ES2323701T3 (en) | 2009-07-23 |
AU2004248863A1 (en) | 2004-12-29 |
JP4619357B2 (en) | 2011-01-26 |
PL1638539T3 (en) | 2009-10-30 |
EP1638539B1 (en) | 2008-12-31 |
PT1638539E (en) | 2009-04-09 |
CA2530736C (en) | 2013-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1638539B1 (en) | Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug | |
JP4302509B2 (en) | Water-soluble stable self-assembled polyelectrolytes | |
Gaucher et al. | Block copolymer micelles: preparation, characterization and application in drug delivery | |
AU2007333528B2 (en) | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles | |
CA2414241C (en) | Polymeric micelle compositions | |
AU2002315598A1 (en) | Water-soluble stabilized self-assembled polyelectrolytes | |
Gautier et al. | Preparation of poly (D, L-lactide) nanoparticles assisted by amphiphilic poly (methyl methacrylate-co-methacrylic acid) copolymers | |
Hu et al. | RTG-loaded nanomicelles (CS–VES–NAC) for oral anti-HIV drug delivery | |
EP3148590A1 (en) | Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules | |
Chatenay-Malabry | CHRISTINE VAUTHIER, PATRICK COUVREUR, and CATHERINE DUBERNET Université de Paris Sud |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004248863 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/014017 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004727195 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2530736 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006515571 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004248863 Country of ref document: AU Date of ref document: 20040414 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004248863 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004727195 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0411872 Country of ref document: BR |